Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kazuhiro Abeyama, William Eng, James V. Jester, Arie A. Vink, Dale Edelbaum, Clay J. Cockerell, Paul R. Bergstresser, Akira Takashima
Published in Volume 105, Issue 12
J Clin Invest. 2000; 105(12):1751–1759 doi:10.1172/JCI9745
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

Pharmacokinetics of NF-κB decoy ODNs. (a) XS106 cells were incubated for the indicated periods with 10 μM FITC-conjugated NF-κB decoy ODNs (open symbols) or scrambled ODNs (closed symbols) at 4°C (triangles) or 37°C (circles) and then analyzed by FACS. Data shown are the mean ± SD (n = 3) of the mean fluorescence intensities (MFI). (b) After 4 hours of incubation with FITC-conjugated NF-κB decoy ODNs at 37°C, XS106 cells were examined by confocal microscopy. (c) XS106 cells were exposed to FS20 sunlamps at 100 J/m2 (reversed triangles), 50 J/m2 (triangles), 25 J/m2 (squares), or 0 J/m2 (circles), cultured in the presence of the indicated concentrations of NF-κB decoy ODNs (open symbols) or scrambled ODNs (closed symbols), and then tested for cell viability by FACS. Data shown are representative of two independent experiments. (d) XS106 cells were exposed to FS20 sunlamps at 50 J/m2 (triangles) or sham-irradiated (circles), cultured for 24 hours in the presence of the indicated concentrations of NF-κB decoy ODNs (open symbols) or scrambled ODNs (closed symbols), and then examined for IL-1β secretion. Data shown are the mean ± SD from triplicate samples.